Written by the Nuvirox Research Team
Key points
- Fisetin was identified as the most potent senolytic among ten flavonoids screened, and extended health and lifespan in mice. That result is real and was widely reported.
- The first completed randomized human trial — a phase I/II study in knee osteoarthritis — found no evidence of benefit for pain, function, or cartilage health.
- The frailty trial everyone cites as evidence, AFFIRM, has been running since 2018 and has not reported. Citing an unreported trial as support is not evidence.
Short answer: promising mechanism, one clean human trial, and it was negative. Fisetin is a flavonoid found in strawberries and persimmons that outperformed nine other flavonoids in a senolytic screen and extended healthspan and lifespan in mice. The senolytic idea — selectively killing the damaged, non-dividing cells that accumulate with age and secrete inflammatory signals — is one of the more mechanistically compelling stories in ageing research. But the first completed randomized, double-blind, placebo-controlled human trial of fisetin reported no significant benefit on any of its main outcomes. That is not a reason to dismiss the field. It is a reason to be honest about where it currently stands.
The senolytic hypothesis and the point at which human evidence currently stops.
What is a senolytic, and why fisetin?
Cells that sustain enough damage stop dividing but do not die. These senescent cells accumulate in tissues with age and secrete a mixture of inflammatory cytokines, chemokines, and matrix-degrading enzymes collectively called the senescence-associated secretory phenotype. The hypothesis is that clearing them should reduce chronic inflammation and improve tissue function.
The original senolytic combination was dasatinib (a leukaemia drug) plus quercetin. Yousefzadeh and colleagues screened a panel of flavonoid polyphenols looking for something more potent and more accessible, and fisetin came out on top. In progeroid mice carrying a p16 reporter and in aged wild-type mice, fisetin reduced senescence markers across multiple tissues and extended health and lifespan.
Fisetin is chemically related to quercetin, which appears in many NAD+ formulas for different reasons. The two share a flavonol backbone and some overlapping activity, though they are not interchangeable.
What human studies actually show
The completed osteoarthritis trial was negative. A phase I/II randomized, double-blind, placebo-controlled trial conducted under FDA IND and IRB approval enrolled adults aged 40 to 80 with radiographically confirmed knee osteoarthritis (Kellgren-Lawrence grades II to IV). Participants received either oral fisetin at 20 mg per kilogram of body weight for two consecutive days, repeated across three cycles with 28 days off between, or matching placebo. Outcomes included adverse events over 12 months, self-reported pain collected every three days initially, and imaging and physical performance at six and twelve months. The investigators reported no significant safety concerns and no evidence of significant benefit for pain, function, or cartilage health.
Study snapshot — fisetin in knee osteoarthritis
| Design | Phase I/II randomized, double-blind, placebo-controlled |
| Participants | Adults 40–80 with K-L grade II–IV knee osteoarthritis |
| Dose | 20 mg/kg for 2 consecutive days × 3 cycles, 28 days off between |
| Duration | 12 months of follow-up |
| Result | No significant safety concerns; no benefit on pain, function, or cartilage |
| Registration | NCT04210986 |
The trial usually cited as evidence has not reported. AFFIRM — a phase 2 randomized placebo-controlled study of fisetin for frailty and inflammation in older women at Mayo Clinic — began enrolling in February 2018 with oral fisetin at 20 mg/kg/day for two days versus placebo. Its estimated primary completion date is November 2026 and full completion November 2027. It is not unblinded. Any article citing AFFIRM as demonstrating that fisetin works is citing a trial that has produced no results.
Senescent cell markers do appear to shift. A review of fisetin as a senotherapeutic noted that in humans, self-administration of 100 mg per day was associated with a reduction in a specific population of senescent peripheral blood mononuclear cells. That is a biomarker observation from an uncontrolled setting, not a clinical outcome, but it suggests the compound is doing something measurable in people.
Trials in other conditions are ongoing. A multi-centre randomized double-blind trial is testing fisetin at 20 mg/kg in elderly patients with sepsis, aiming to enrol 220 participants. Whether senolytics help in acute illness is a genuinely open question, and that trial will be informative regardless of direction.
What fisetin will not do
It will not reliably reach the concentrations used in the mouse work. Reviewers consistently flag fisetin’s low oral bioavailability and rapid metabolism as the central obstacle to clinical translation. It is extensively glucuronidated and sulfated on first pass, and free plasma concentrations are low and short-lived. The 20 mg/kg doses in trials — around 1,400 mg for a 70 kg adult — are far above what most commercial capsules provide.
It will not give you a way to know whether it worked. There is no validated, accessible measure of senescent cell burden available to consumers. Reviewers explicitly note that reliable, sensitive measures of senolytic efficacy remain to be validated. You would be taking it on faith, indefinitely, with no feedback.
It will not address fatigue, and nobody has tested that. If tiredness is your concern, the senescence literature is a poor place to look for answers, and the ordinary medical causes deserve attention first.
If you are considering it anyway
The dosing schedule used in trials is unusual and worth understanding: high doses for two consecutive days, then weeks off. This reflects the hit-and-run senolytic model, in which the goal is to kill a population of cells rather than maintain a steady drug level. Daily low-dose supplementation is not what the trials tested and is not the same intervention.
Fisetin appears well tolerated at trial doses — the osteoarthritis trial reported no significant safety concerns over twelve months, and the sepsis and COVID protocols noted no severe or serious adverse events attributed to it. That is genuine reassurance about short-term tolerability. It is not evidence of benefit, and the two are frequently conflated in supplement marketing.
If you are on medications metabolised through cytochrome P450 enzymes or on anticoagulants, flavonoids at gram-level doses are worth raising with your prescriber.
Frequently asked questions
Does fisetin actually work in humans?
On the only completed randomized trial with clinical endpoints, no — it did not improve pain, function, or cartilage health in knee osteoarthritis. Biomarker data suggest it does something to senescent cell populations. Those are different claims.
How much fisetin did the trials use?
20 mg per kilogram of body weight for two consecutive days, repeated in cycles with roughly a month between. For a 70 kg adult that is about 1,400 mg per dosing day, considerably more than typical capsule strengths.
Is fisetin better than quercetin?
In the original flavonoid screen fisetin was the most potent senolytic of the ten tested, including quercetin. That was in cell and mouse models. No human trial has compared them.
Why is fisetin so hard to absorb?
It undergoes extensive first-pass conjugation, and free plasma concentrations fall quickly. Reviewers identify this as a primary barrier to translating the mouse results, and it is why some formulations use liposomal or phospholipid delivery.
When will we know more?
The AFFIRM frailty trial has an estimated primary completion date of November 2026. The sepsis trial is enrolling. Both should meaningfully change the picture.
From Nuvirox
Why we formulated NAD+ Restore
- 500 mg nicotinamide riboside chloride (NR) — one of the two most-researched NAD+ precursors, within the dose range used in published human trials.
- 150 mg trans-resveratrol (Japanese knotweed) and 50 mg quercetin (Sophora japonica) — polyphenols studied alongside NAD+ pathways for cellular health support.
- 10 mg galactomannans from fenugreek to support absorption.
- 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should.
The bottom line
Fisetin is a serious research compound with a genuinely interesting mechanism and a disappointing first result. The mouse data were strong, the senolytic hypothesis remains worth testing, and the field deserves the trials it is running. But the honest state of play in mid-2026 is one completed randomized human trial reporting no benefit, one long-running frailty trial that has not read out, and a bioavailability problem nobody has solved. Buying fisetin today means betting on trials that have not reported yet.
References
- Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18-28
- Results from a randomized clinical trial evaluating the senolytic fisetin for treating knee osteoarthritis. Osteoarthritis and Cartilage. 2025;33(Suppl). DOI: 10.1016/j.joca.2025.01.xxx (article S1063-4584(25)00692-2). ClinicalTrials.gov: NCT04210986
- AFFIRM: A phase 2 randomized, placebo-controlled study of alleviation by fisetin of frailty, inflammation, and related measures in older women. Mayo Clinic. ClinicalTrials.gov: NCT03430037 (estimated primary completion November 2026)
- Fisetin as a senotherapeutic agent: evidence and perspectives for age-related diseases. Mechanisms of Ageing and Development. 2024. DOI: 10.1016/j.mad.2024.111995
- Senolytics to slow progression of sepsis (STOP-Sepsis) in elderly patients: study protocol for a multicenter, randomized, adaptive allocation clinical trial. 2024. PMID: 39434114. ClinicalTrials.gov: NCT05758246
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.